Ken Griffin Cor Medix Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$3.64 - $8.23 $6,916 - $15,637	1,900 Added 11.18%	18,900 $152,000
Q2 2024 Aug 14, 2024	SELL	$4.08 - $6.39 $53,856 - $84,348	-13,200 Reduced 43.71%	17,000 $73,000
Q1 2024 May 15, 2024	BUY	$2.94 - $4.24 $65,562 - $94,552	22,300 Added 282.28%	30,200 $128,000
Q4 2023 Feb 14, 2024	SELL	$3.0 - $4.01 $71,400 - $95,438	-23,800 Reduced 75.08%	7,900 $29,000
Q3 2023 Nov 14, 2023	SELL	$3.6 - $4.46 $42,480 - $52,628	-11,800 Reduced 27.13%	31,700 $117,000
Q2 2023 Aug 14, 2023	SELL	$3.94 - $5.8 $5,516 - $8,120	-1,400 Reduced 3.12%	43,500 $172,000
Q1 2023 May 15, 2023	BUY	$3.22 - $4.61 $105,294 - $150,747	32,700 Added 268.03%	44,900 $185,000
Q4 2022 Feb 14, 2023	SELL	$2.81 - $4.45 $47,770 - $75,650	-17,000 Reduced 58.22%	12,200 $51,000
Q3 2022 Nov 14, 2022	BUY	$2.82 - $7.52 $6,486 - $17,296	2,300 Added 8.55%	29,200 $83,000

104

17.4M

134K

441K

Ticker CRMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,208,200
Market Cap $410M
Description
CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of cathet...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.